These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101 [TBL] [Abstract][Full Text] [Related]
13. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471 [TBL] [Abstract][Full Text] [Related]
15. Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients. Polanco D; Pinilla L; Gracia-Lavedan E; Gatius S; Zuil M; Pardina M; Gómez S; Barbé F J Cancer Res Clin Oncol; 2023 Oct; 149(13):12459-12468. PubMed ID: 37450028 [TBL] [Abstract][Full Text] [Related]
16. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Sakakibara R; Inamura K; Tambo Y; Ninomiya H; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Matsuura Y; Nakao M; Mun M; Okumura S; Inase N; Nishio M; Motoi N; Ishikawa Y Clin Lung Cancer; 2017 Sep; 18(5):527-534.e1. PubMed ID: 28111119 [TBL] [Abstract][Full Text] [Related]
17. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study. Murthy V; Katzman DP; Tsay JJ; Bessich JL; Michaud GC; Rafeq S; Minehart J; Mangalick K; de Lafaille MAC; Goparaju C; Pass H; Sterman DH Lung Cancer; 2019 Nov; 137():94-99. PubMed ID: 31563736 [TBL] [Abstract][Full Text] [Related]
18. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496 [TBL] [Abstract][Full Text] [Related]
19. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671 [TBL] [Abstract][Full Text] [Related]